

(19)



(11)

EP 1 829 550 A2

(12)

## EUROPEAN PATENT APPLICATION

(43) Date of publication:

05.09.2007 Bulletin 2007/36

(21) Application number: 07006886.1

(22) Date of filing: 25.09.1997

(51) Int Cl.:

*A61K 38/00 (2006.01)* *A61K 33/00 (2006.01)*  
*A61K 38/02 (2006.01)* *A61K 38/17 (2006.01)*  
*A61K 38/36 (2006.01)* *A61K 38/48 (2006.01)*  
*A61K 39/395 (2006.01)* *C07K 5/00 (2006.01)*  
*C07K 14/00 (2006.01)* *C07K 14/435 (2006.01)*  
*C07K 14/745 (2006.01)* *C07K 16/00 (2006.01)*  
*C07K 16/18 (2006.01)* *C07K 16/28 (2006.01)*  
*G01N 33/50 (2006.01)*

(84) Designated Contracting States:

AT BE CH DE DK ES FI FR GB GR IE IT LI LU MC  
NL PT SE

(30) Priority: 27.09.1996 US 721447

(62) Document number(s) of the earlier application(s) in accordance with Art. 76 EPC:

97944453.6 / 0 951 292

(71) Applicant: The Trustees of Columbia University in the City of New York  
New York, NY 10027-6699 (US)

(72) Inventors:

- Pinsky, David J.  
48105, Michigan (US)
- Stern, David  
30910, Georgia (US)
- Prestigiacomo, Charles J.  
07936, New Jersey (US)

(74) Representative: Vossius & Partner  
Siebertstrasse 4  
81675 München (DE)

### Remarks:

This application was filed on 02 - 04 - 2007 as a divisional application to the application mentioned under INID code 62.

### (54) Methods for treating an Ischemic disorder and improving stroke outcome

(57) The present invention provides for a method for treating an ischemic disorder in a subject which comprises administering to the subject a pharmaceutically acceptable form of a selection antagonist in a sufficient amount over a sufficient time period to prevent white blood cell accumulation so as to treat the ischemic disorder in the subject. The invention further provides a method for treating an ischemic disorder in a subject which comprises administering to the subject carbon monoxide gas in a

sufficient amount over a sufficient period of time thereby treating the ischemic disorder in the subject. The invention further provides a method for treating an ischemic disorder in a subject which comprises administering to the subject a pharmaceutically acceptable form of inactivated Factor IX in a sufficient amount over a sufficient period of time to inhibit coagulation so as to treat the ischemic disorder in the subject.

EP 1 829 550 A2

Applicants: David J. Pinsky et al.  
Serial No.: 10/679,135  
Filed: October 3, 2003  
Exhibit 3